MENU

Create
Your Most
Valuable Plan

Multiple myeloma shouldn’t be navigated alone. It’s a complex disease, but the right management strategy can help. Introducing Myeloma MVP – your Most Valuable Plan to help you prioritize and achieve your treatment goals.

Start building your planMeet our team

Thank you!

We look forward to sharing updates in the future

Close window

Sign up to learn more and receive email updates from Myeloma Explained.

References

  1. National Cancer Institute. Myeloma Cancer Stat Facts. Available at: www.seer.cancer.gov/statfacts/html/mulmy.html. Accessed on: May 29, 2018.
  2. Ailawadhi S, Swaika A, Advani P, et. al. Current State of Patient Awareness and Participation in Care for Multiple Myeloma and the Psychophysical Impact of Treatment: An International Internet-Based Study. Blood. 2014;124:1294.
  3. Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin in Hematol. 2012, 49 (Suppl 1):S16-S32.
  4. American Cancer Society. About Multiple Myeloma. Available at https://www.cancer.org/content/dam/CRC/PDF/Public/8738.00.pdf. Accessed on May 2, 2018.
  5. The Multiple Myeloma Research Foundation. Multiple Myeloma Disease Overview. Available at https://www.themmrf.org/assets/mmrf-disease-overview.pdf. Accessed on May 2, 2018.
  6. American Cancer Society. Signs and Symptoms of Multiple Myeloma. Available at https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/signs-symptoms.html. Accessed on May 2, 2018.
  7. American Cancer Society. Risk Factors for Multiple Myeloma. Available at: https://www.cancer.org/cancer/multiple-myeloma/causes-risks-prevention/risk-factors.html. Accessed on May 2, 2018.
  8. National Cancer Institute. Understanding Cancer Prognosis. Available at https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis#cure-remission-difference. Accessed on June 1, 2018.
  9. Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2015; 30(5):1005-17.
  10. Durie BGM. Multiple Myeloma - Concise Review of the Disease and Treatment Options, 2017 Edition. International Myeloma Foundation. Accessed 06/13/2018.
  11. American Cancer Society. Drug Therapy for Multiple Myeloma. Available at https://www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy.html. Accessed on May 2, 2018.
  12. The Multiple Myeloma Research Foundation. Standard Treatments. Available at https://themmrf.org/multiple-myeloma/treatment-options/standard-treatments/. Accessed on May 2, 2018.
  13. Quach H, Ritchie D, Stewart SK, et. Al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010 24(1): 22–32.
  14. Terpos E, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347-57.
  15. NIH. Iron-Deficiency Anemia: Signs, Symptoms, and Complications. Available at https://www.nhlbi.nih.gov/health-topics/iron-deficiency-anemia. Accessed on May 2, 2018.
  16. Bhowmik D, et al. Prevalence Of Renal Impairment In Patients With Multiple Myeloma: Analysis Of Real-World Database. Journal of the International Society for Pharmacoeconomic and Outcomes Research. 2016;9(3):A141.
  17. Blimark C, Holmberg E, Mellqvist UH, et. al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100 (1) 107-113.

You are now leaving MyelomaExplained.com and going to a website.

Would you like to proceed?

YesCancel

You are now leaving MyelomaExplained.com.

The sponsors of this site are not responsible for content on the site you are about to enter. Would you like to proceed?

YesCancel